logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HPV+ OPSCC: cetuximab inferior to cisplatin for CRT

Findings suggest that cisplatin should remain the standard of care in eligible patients.